Clinical Trials
Cysteamine bitartrate has been evaluated across numerous Phase 1, Phase 2, and Phase 3 clinical trials for cystinosis, alongside exploratory indications including nonalcoholic fatty liver disease, asthma, inherited mitochondrial diseases such as Leigh syndrome, major depressive disorder, and schizophrenia. Supported by diverse academic, governmental, and industrial sponsors—including Amgen, Nacuity Pharmaceuticals, the Icahn School of Medicine at Mount Sinai, and the National Institute of Diabetes and Digestive and Kidney Diseases—these investigations span completed, active, terminated, and unknown recruitment statuses.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05994534 | ACTIVE_NOT_RECRUITING | Cystinosis |
Nacuity Pharmaceuticals, Inc. |
2023-10-29 | PHASE1; PHASE2 |
| NCT03883984 | COMPLETED | Asthma |
Children's Hospital Medical Center, Cincinnati |
2019-06-18 | PHASE1 |
| NCT01197378 | COMPLETED | Cystinosis |
Amgen |
2010-08-27 | PHASE3 |
| NCT02473445 | TERMINATED | Mitochondrial Diseases |
Amgen |
2015-05-19 | PHASE2 |
| NCT01744782 | COMPLETED | Cystinosis |
Amgen |
2012-12-20 | PHASE3 |
| NCT02012114 | COMPLETED | Cystinosis |
Hospices Civils de Lyon |
2011-12 | |
| NCT02023866 | COMPLETED | Inherited Mitochondrial Disease, Including Leigh Syndrome |
Amgen |
2014-05 | PHASE2 |
| NCT01529268 | COMPLETED | Nonalcoholic Fatty Liver Disease (NAFLD) |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2012-06 | PHASE2; PHASE3 |
| NCT01733316 | COMPLETED | Cystinosis |
Amgen |
2013-01-31 | PHASE3 |
| NCT01139125 | TERMINATED | Schizophrenia; Schizoaffective |
Augusta University |
2009-09 | |
| NCT01432561 | COMPLETED | Cystinosis; Nephropathic Cystinosis |
University of California, San Diego |
2011-09 | |
| NCT01000961 | COMPLETED | Cystinosis |
Amgen |
2010-06 | PHASE3 |
| NCT00872729 | COMPLETED | Cystinosis |
Amgen |
2009-05 | PHASE1; PHASE2 |
| NCT00715559 | TERMINATED | Major Depressive Disorder |
Icahn School of Medicine at Mount Sinai |
2008-07 |
(data from https://clinicaltrials.gov, updated on 2026-06-30)
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Jump to
- Cysteamine bitartrate Solubility in DMSO
- Cysteamine bitartrate Stock Solution
- Cysteamine bitartrate Storage
- Cysteamine bitartrate Stability
- Cysteamine bitartrate Molecular Weight
- Cysteamine bitartrate SMILES
- Cysteamine bitartrate CAS Number
- Cysteamine bitartrate Chemical Structure (2D and 3D)
- Cysteamine bitartrate SDS|MSDS